Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy

Objective: Abnormal autophagic function and activated inflammasomes are typical features in the liver of patients with non-alcoholic steatohepatitis (NASH). Here, we explored whether gemigliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor for treatment of type 2 diabetes, can induce autophagy and reg...

Full description

Bibliographic Details
Main Authors: Youngmi Song, Hyekyung Yang, Juhee Kim, Yoonjin Lee, Sung-Ho Kim, In-Gu Do, Cheol-Young Park
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Metabolism
Subjects:
Gemigliptin
DPP-4 inhibitor
ULK-1
Autophagy
NASH
Inflammasome
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877823001400

Similar Items

Similar Items